Table 1. Patient demographics and baseline characteristics and comparison to VIVID and VISTA participants.
| Characteristic | NWL | VISTA | VIVID |
|---|---|---|---|
| (patient, n = 221 eyes, n = 270) | IAI 2q8 (eyes, n = 151) | IAI 2q8 (eyes, n = 135) | |
| Mean age, years (SD) | 62.8 (12.6) | 63.1 (9.4) | 64.2 (7.8) |
| Sex, n (%) | |||
| Male | 147 (66.5) | 78 (51.7) | 88 (65.2) |
| Female | 74 (33.5) | 73 (48.3) | 47 (34.8) |
| Ethnicity, n (%) | |||
| Black | 48 (21.7) | 19 (12.6) | 1 (0.7) |
| White | 62 (28.0) | 125 (82.8) | 106 (78.5) |
| Far East Asian | 11 (5.0) | 2 (1.3) ** | 27 (20.0) ** |
| South Asian | 78 (35.3) | ||
| Other | - | 5 (3.3) | 1 (0.7) |
| Unknown | 22 (10.0) | - | - |
| Mean HbA1c, % (SD) | 8.3 (4) | 7.9 (1.6) | 7.7 (1.4) |
| Mean eGFR | 72 | - | - |
| Mean creatinine | 88 | - | - |
| Retinopathy status, n (%) | |||
| R0 | 0 (0) | 4 (2.6) | 0 (0) |
| R1 | 62 (22.9) | 64 (42.4) | 29 (21.4) |
| R2 | 150 (55.6) | 72 (47.7) | 69 (51.1) |
| R3A | 43 (15.9) | 8 (5.3) | 3 (2.2) |
| R3S | 14 (5.2) | - | - |
| Ungradable | - | 3 (2.0) | 34 (25.2) |
| Lens status, n (%) | |||
| Phakic | 208 (77.0) | - | - |
| Pseudophakic | 51 (18.9) | - | - |
| Mean BCVA, letters (SD) | 66.4 (14.6) | 59.4 (10.9) | 58.8 (11.2) |
| Mean central retinal thickness, μm (SD) | 418 (94.0) | 479 (154) | 518 (147) |
| Mean injections, n (SD) | 6.2 (2.3) | 8.4 (1.3) | 8.7 (1.2) |
NWL- North West London data set; IAI 2q8 –Cohort of patients receiving 2mg intravitreal aflibercept (IAI) every 4 weeks from baseline to week 16 (5 doses) followed by dosing every 8 weeks through week 48; SD–Standard Deviation; HbA1c- Glycated haemoglobin; eGFR–Estimated Glomerular Filtration Rate; R0- No retinopathy; R1- Background retinopathy; R2- Pre-proliferative retinopathy; R3A- Active proliferative retinopathy; R3S- Stable proliferative retinopathy; BCVA- Best Corrected Visual Acuity.
**In VIVID and VISTA studies [18] “Asian” subgroups were not differentiated.